Tracks safety and effectiveness of Ozempic in routine care for type 2 diabetes
Observes adults with type 2 diabetes starting Ozempic (semaglutide) as prescribed in usual care.
Plain-language title generated from the registry record
Registry title: Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Key facts
- Where
- Jeonlabuk-do, South KoreaSee the site
Where in South Korea
- Wonkwang University HospitalJeonlabuk-do, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT05689372
- Record updated
- 5 May 2026
- Original description
The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.Read full original descriptionShow less
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.
Inclusion: The decision to initiate treatment with commercially available Ozempic has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study; The participant with T2DM is scheduled to start treatment with Ozempic based on the clinical judgment of their treating physician as specified in the approved label in Korea; Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; Male/female age greater than or equal to (>=) 19 years at the time of signing informed consent.
Exclusion: Participants who are or have previously been on Ozempic therapy; Previous participation in this study. Participation is defined as having given informed consent in this study; Known or suspected hypersensitivity to Ozempic, the active substance or any of the excipients; Female patients who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice); Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.